	title	geo_accession	status	submission_date	last_update_date	type	channel_count	source_name_ch1	organism_ch1	characteristics_ch1	characteristics_ch1	characteristics_ch1	characteristics_ch1	treatment_protocol_ch1	molecule_ch1	extract_protocol_ch1	label_ch1	label_protocol_ch1	taxid_ch1	hyb_protocol	scan_protocol	description	data_processing	platform_id	contact_name	contact_email	contact_phone	contact_laboratory	contact_department	contact_institute	contact_address	contact_city	contact_state	contact_zip/postal_code	contact_country	supplementary_file	data_row_count
GSM417411	Patient 01-D0	GSM417411	Public on Jun 20 2009	Jun 15 2009	Jun 19 2009	RNA	1	Day 0	Homo sapiens	diagnosis: AML-TLD	cell type: CD34+	dose: 50 mg/m2/day 5-azacytidine	dose: 2 mg/m2/day entinostat	Enrolled patients were treated with sequential administration of 5AC and entinostat.  The study was approved by the Institutional Review Boards (IRB) for each institution, and all patients signed informed consent according to Health and Human Services guidelines.  Specific IRB approved informed consent was obtained for the laboratory research use of patient specimens.  5AC was administered subcutaneously for 10 consecutive days in doses of 30, 40, or 50 mg/m2/day.  Entinostat (2, 4, 6, or 8 mg/m2) was administered orally on days 3 and 10 of the 5AC treatment schedule in the course of a 28-29 day treatment cycle.	total RNA	RNA was isolated using Qiagen RNeasy Mini Kit with on-column DNAse treatment to remove genomic DNA	biotin	mRNA was subjected to two rounds of linear amplification and biotin labelling in second round was with the Ambion MessageAmp II kit with bio-C and bio-U as stated by manufacturer	9606	Hybridization cocktails containing 10 ug of fragmented cRNA was prepared using GeneChip Expression 3'-Amplification Reagents Hybridization Control Kit in a 200 ul final volume according to the manufacturers instructions	Affymetrix standard scanning protocol	Patients with MDS, chronic myelomonocytic leukemia (CMMoL), and high risk AML were treated with sequential administration of methylation inhibitor drugs (5AC and entinostat).	Cel files were imported in GeneSpring GX and normalized by GC-RMA. Pairs of specimens passing quality control for hybridization and RNA integrity were analyzed by paired T test	GPL570	Weijia,,Zhang	weijia.zhang@mssm.edu	212-241-2883	Bioinformatics Lab	Department of Medicine	Mount Sinai School of Medicine	1425 Madison Avenue	New York	NY	10029	USA	ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM417nnn/GSM417411/GSM417411.CEL.gz	54675
GSM417412	Patient 01-D15	GSM417412	Public on Jun 20 2009	Jun 15 2009	Jun 19 2009	RNA	1	Day 15	Homo sapiens	diagnosis: AML-TLD	cell type: CD34+	dose: 50 mg/m2/day 5-azacytidine	dose: 2 mg/m2/day entinostat	Enrolled patients were treated with sequential administration of 5AC and entinostat.  The study was approved by the Institutional Review Boards (IRB) for each institution, and all patients signed informed consent according to Health and Human Services guidelines.  Specific IRB approved informed consent was obtained for the laboratory research use of patient specimens.  5AC was administered subcutaneously for 10 consecutive days in doses of 30, 40, or 50 mg/m2/day.  Entinostat (2, 4, 6, or 8 mg/m2) was administered orally on days 3 and 10 of the 5AC treatment schedule in the course of a 28-29 day treatment cycle.	total RNA	RNA was isolated using Qiagen RNeasy Mini Kit with on-column DNAse treatment to remove genomic DNA	biotin	mRNA was subjected to two rounds of linear amplification and biotin labelling in second round was with the Ambion MessageAmp II kit with bio-C and bio-U as stated by manufacturer	9606	Hybridization cocktails containing 10 ug of fragmented cRNA was prepared using GeneChip Expression 3'-Amplification Reagents Hybridization Control Kit in a 200 ul final volume according to the manufacturers instructions	Affymetrix standard scanning protocol	Patients with MDS, chronic myelomonocytic leukemia (CMMoL), and high risk AML were treated with sequential administration of methylation inhibitor drugs (5AC and entinostat).	Cel files were imported in GeneSpring GX and normalized by GC-RMA. Pairs of specimens passing quality control for hybridization and RNA integrity were analyzed by paired T test	GPL570	Weijia,,Zhang	weijia.zhang@mssm.edu	212-241-2883	Bioinformatics Lab	Department of Medicine	Mount Sinai School of Medicine	1425 Madison Avenue	New York	NY	10029	USA	ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM417nnn/GSM417412/GSM417412.CEL.gz	54675
GSM417413	Patient 02-D0	GSM417413	Public on Jun 20 2009	Jun 15 2009	Jun 19 2009	RNA	1	Day 0	Homo sapiens	diagnosis: AML-TLD	cell type: CD34+	dose: 50 mg/m2/day 5-azacytidine	dose: 2 mg/m2/day entinostat	Enrolled patients were treated with sequential administration of 5AC and entinostat.  The study was approved by the Institutional Review Boards (IRB) for each institution, and all patients signed informed consent according to Health and Human Services guidelines.  Specific IRB approved informed consent was obtained for the laboratory research use of patient specimens.  5AC was administered subcutaneously for 10 consecutive days in doses of 30, 40, or 50 mg/m2/day.  Entinostat (2, 4, 6, or 8 mg/m2) was administered orally on days 3 and 10 of the 5AC treatment schedule in the course of a 28-29 day treatment cycle.	total RNA	RNA was isolated using Qiagen RNeasy Mini Kit with on-column DNAse treatment to remove genomic DNA	biotin	mRNA was subjected to two rounds of linear amplification and biotin labelling in second round was with the Ambion MessageAmp II kit with bio-C and bio-U as stated by manufacturer	9606	Hybridization cocktails containing 10 ug of fragmented cRNA was prepared using GeneChip Expression 3'-Amplification Reagents Hybridization Control Kit in a 200 ul final volume according to the manufacturers instructions	Affymetrix standard scanning protocol	Patients with MDS, chronic myelomonocytic leukemia (CMMoL), and high risk AML were treated with sequential administration of methylation inhibitor drugs (5AC and entinostat).	Cel files were imported in GeneSpring GX and normalized by GC-RMA. Pairs of specimens passing quality control for hybridization and RNA integrity were analyzed by paired T test	GPL570	Weijia,,Zhang	weijia.zhang@mssm.edu	212-241-2883	Bioinformatics Lab	Department of Medicine	Mount Sinai School of Medicine	1425 Madison Avenue	New York	NY	10029	USA	ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM417nnn/GSM417413/GSM417413.CEL.gz	54675
GSM417414	Patient 02-D15	GSM417414	Public on Jun 20 2009	Jun 15 2009	Jun 19 2009	RNA	1	Day 15	Homo sapiens	diagnosis: AML-TLD	cell type: CD34+	dose: 50 mg/m2/day 5-azacytidine	dose: 2 mg/m2/day entinostat	Enrolled patients were treated with sequential administration of 5AC and entinostat.  The study was approved by the Institutional Review Boards (IRB) for each institution, and all patients signed informed consent according to Health and Human Services guidelines.  Specific IRB approved informed consent was obtained for the laboratory research use of patient specimens.  5AC was administered subcutaneously for 10 consecutive days in doses of 30, 40, or 50 mg/m2/day.  Entinostat (2, 4, 6, or 8 mg/m2) was administered orally on days 3 and 10 of the 5AC treatment schedule in the course of a 28-29 day treatment cycle.	total RNA	RNA was isolated using Qiagen RNeasy Mini Kit with on-column DNAse treatment to remove genomic DNA	biotin	mRNA was subjected to two rounds of linear amplification and biotin labelling in second round was with the Ambion MessageAmp II kit with bio-C and bio-U as stated by manufacturer	9606	Hybridization cocktails containing 10 ug of fragmented cRNA was prepared using GeneChip Expression 3'-Amplification Reagents Hybridization Control Kit in a 200 ul final volume according to the manufacturers instructions	Affymetrix standard scanning protocol	Patients with MDS, chronic myelomonocytic leukemia (CMMoL), and high risk AML were treated with sequential administration of methylation inhibitor drugs (5AC and entinostat).	Cel files were imported in GeneSpring GX and normalized by GC-RMA. Pairs of specimens passing quality control for hybridization and RNA integrity were analyzed by paired T test	GPL570	Weijia,,Zhang	weijia.zhang@mssm.edu	212-241-2883	Bioinformatics Lab	Department of Medicine	Mount Sinai School of Medicine	1425 Madison Avenue	New York	NY	10029	USA	ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM417nnn/GSM417414/GSM417414.CEL.gz	54675
GSM417415	Patient 03-D0	GSM417415	Public on Jun 20 2009	Jun 15 2009	Jun 19 2009	RNA	1	Day 0	Homo sapiens	diagnosis: AML-TLD	cell type: CD34+	dose: 50 mg/m2/day 5-azacytidine	dose: 2 mg/m2/day entinostat	Enrolled patients were treated with sequential administration of 5AC and entinostat.  The study was approved by the Institutional Review Boards (IRB) for each institution, and all patients signed informed consent according to Health and Human Services guidelines.  Specific IRB approved informed consent was obtained for the laboratory research use of patient specimens.  5AC was administered subcutaneously for 10 consecutive days in doses of 30, 40, or 50 mg/m2/day.  Entinostat (2, 4, 6, or 8 mg/m2) was administered orally on days 3 and 10 of the 5AC treatment schedule in the course of a 28-29 day treatment cycle.	total RNA	RNA was isolated using Qiagen RNeasy Mini Kit with on-column DNAse treatment to remove genomic DNA	biotin	mRNA was subjected to two rounds of linear amplification and biotin labelling in second round was with the Ambion MessageAmp II kit with bio-C and bio-U as stated by manufacturer	9606	Hybridization cocktails containing 10 ug of fragmented cRNA was prepared using GeneChip Expression 3'-Amplification Reagents Hybridization Control Kit in a 200 ul final volume according to the manufacturers instructions	Affymetrix standard scanning protocol	Patients with MDS, chronic myelomonocytic leukemia (CMMoL), and high risk AML were treated with sequential administration of methylation inhibitor drugs (5AC and entinostat).	Cel files were imported in GeneSpring GX and normalized by GC-RMA. Pairs of specimens passing quality control for hybridization and RNA integrity were analyzed by paired T test	GPL570	Weijia,,Zhang	weijia.zhang@mssm.edu	212-241-2883	Bioinformatics Lab	Department of Medicine	Mount Sinai School of Medicine	1425 Madison Avenue	New York	NY	10029	USA	ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM417nnn/GSM417415/GSM417415.CEL.gz	54675
GSM417416	Patient 03-D15	GSM417416	Public on Jun 20 2009	Jun 15 2009	Jun 19 2009	RNA	1	Day 15	Homo sapiens	diagnosis: AML-TLD	cell type: CD34+	dose: 50 mg/m2/day 5-azacytidine	dose: 2 mg/m2/day entinostat	Enrolled patients were treated with sequential administration of 5AC and entinostat.  The study was approved by the Institutional Review Boards (IRB) for each institution, and all patients signed informed consent according to Health and Human Services guidelines.  Specific IRB approved informed consent was obtained for the laboratory research use of patient specimens.  5AC was administered subcutaneously for 10 consecutive days in doses of 30, 40, or 50 mg/m2/day.  Entinostat (2, 4, 6, or 8 mg/m2) was administered orally on days 3 and 10 of the 5AC treatment schedule in the course of a 28-29 day treatment cycle.	total RNA	RNA was isolated using Qiagen RNeasy Mini Kit with on-column DNAse treatment to remove genomic DNA	biotin	mRNA was subjected to two rounds of linear amplification and biotin labelling in second round was with the Ambion MessageAmp II kit with bio-C and bio-U as stated by manufacturer	9606	Hybridization cocktails containing 10 ug of fragmented cRNA was prepared using GeneChip Expression 3'-Amplification Reagents Hybridization Control Kit in a 200 ul final volume according to the manufacturers instructions	Affymetrix standard scanning protocol	Patients with MDS, chronic myelomonocytic leukemia (CMMoL), and high risk AML were treated with sequential administration of methylation inhibitor drugs (5AC and entinostat).	Cel files were imported in GeneSpring GX and normalized by GC-RMA. Pairs of specimens passing quality control for hybridization and RNA integrity were analyzed by paired T test	GPL570	Weijia,,Zhang	weijia.zhang@mssm.edu	212-241-2883	Bioinformatics Lab	Department of Medicine	Mount Sinai School of Medicine	1425 Madison Avenue	New York	NY	10029	USA	ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM417nnn/GSM417416/GSM417416.CEL.gz	54675
GSM417417	Patient 04-D0	GSM417417	Public on Jun 20 2009	Jun 15 2009	Jun 19 2009	RNA	1	Day 0	Homo sapiens	diagnosis: MDS	cell type: CD34+	dose: 40 mg/m2/day 5-azacytidine	dose: 2 mg/m2/day entinostat	Enrolled patients were treated with sequential administration of 5AC and entinostat.  The study was approved by the Institutional Review Boards (IRB) for each institution, and all patients signed informed consent according to Health and Human Services guidelines.  Specific IRB approved informed consent was obtained for the laboratory research use of patient specimens.  5AC was administered subcutaneously for 10 consecutive days in doses of 30, 40, or 50 mg/m2/day.  Entinostat (2, 4, 6, or 8 mg/m2) was administered orally on days 3 and 10 of the 5AC treatment schedule in the course of a 28-29 day treatment cycle.	total RNA	RNA was isolated using Qiagen RNeasy Mini Kit with on-column DNAse treatment to remove genomic DNA	biotin	mRNA was subjected to two rounds of linear amplification and biotin labelling in second round was with the Ambion MessageAmp II kit with bio-C and bio-U as stated by manufacturer	9606	Hybridization cocktails containing 10 ug of fragmented cRNA was prepared using GeneChip Expression 3'-Amplification Reagents Hybridization Control Kit in a 200 ul final volume according to the manufacturers instructions	Affymetrix standard scanning protocol	Patients with MDS, chronic myelomonocytic leukemia (CMMoL), and high risk AML were treated with sequential administration of methylation inhibitor drugs (5AC and entinostat).	Cel files were imported in GeneSpring GX and normalized by GC-RMA. Pairs of specimens passing quality control for hybridization and RNA integrity were analyzed by paired T test	GPL570	Weijia,,Zhang	weijia.zhang@mssm.edu	212-241-2883	Bioinformatics Lab	Department of Medicine	Mount Sinai School of Medicine	1425 Madison Avenue	New York	NY	10029	USA	ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM417nnn/GSM417417/GSM417417.CEL.gz	54675
GSM417418	Patient 04-D15	GSM417418	Public on Jun 20 2009	Jun 15 2009	Jun 19 2009	RNA	1	Day 15	Homo sapiens	diagnosis: MDS	cell type: CD34+	dose: 40 mg/m2/day 5-azacytidine	dose: 2 mg/m2/day entinostat	Enrolled patients were treated with sequential administration of 5AC and entinostat.  The study was approved by the Institutional Review Boards (IRB) for each institution, and all patients signed informed consent according to Health and Human Services guidelines.  Specific IRB approved informed consent was obtained for the laboratory research use of patient specimens.  5AC was administered subcutaneously for 10 consecutive days in doses of 30, 40, or 50 mg/m2/day.  Entinostat (2, 4, 6, or 8 mg/m2) was administered orally on days 3 and 10 of the 5AC treatment schedule in the course of a 28-29 day treatment cycle.	total RNA	RNA was isolated using Qiagen RNeasy Mini Kit with on-column DNAse treatment to remove genomic DNA	biotin	mRNA was subjected to two rounds of linear amplification and biotin labelling in second round was with the Ambion MessageAmp II kit with bio-C and bio-U as stated by manufacturer	9606	Hybridization cocktails containing 10 ug of fragmented cRNA was prepared using GeneChip Expression 3'-Amplification Reagents Hybridization Control Kit in a 200 ul final volume according to the manufacturers instructions	Affymetrix standard scanning protocol	Patients with MDS, chronic myelomonocytic leukemia (CMMoL), and high risk AML were treated with sequential administration of methylation inhibitor drugs (5AC and entinostat).	Cel files were imported in GeneSpring GX and normalized by GC-RMA. Pairs of specimens passing quality control for hybridization and RNA integrity were analyzed by paired T test	GPL570	Weijia,,Zhang	weijia.zhang@mssm.edu	212-241-2883	Bioinformatics Lab	Department of Medicine	Mount Sinai School of Medicine	1425 Madison Avenue	New York	NY	10029	USA	ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM417nnn/GSM417418/GSM417418.CEL.gz	54675
GSM417419	Patient 05-D0	GSM417419	Public on Jun 20 2009	Jun 15 2009	Jun 19 2009	RNA	1	Day 0	Homo sapiens	diagnosis: MDS	cell type: CD34+	dose: 40 mg/m2/day 5-azacytidine	dose: 2 mg/m2/day entinostat	Enrolled patients were treated with sequential administration of 5AC and entinostat.  The study was approved by the Institutional Review Boards (IRB) for each institution, and all patients signed informed consent according to Health and Human Services guidelines.  Specific IRB approved informed consent was obtained for the laboratory research use of patient specimens.  5AC was administered subcutaneously for 10 consecutive days in doses of 30, 40, or 50 mg/m2/day.  Entinostat (2, 4, 6, or 8 mg/m2) was administered orally on days 3 and 10 of the 5AC treatment schedule in the course of a 28-29 day treatment cycle.	total RNA	RNA was isolated using Qiagen RNeasy Mini Kit with on-column DNAse treatment to remove genomic DNA	biotin	mRNA was subjected to two rounds of linear amplification and biotin labelling in second round was with the Ambion MessageAmp II kit with bio-C and bio-U as stated by manufacturer	9606	Hybridization cocktails containing 10 ug of fragmented cRNA was prepared using GeneChip Expression 3'-Amplification Reagents Hybridization Control Kit in a 200 ul final volume according to the manufacturers instructions	Affymetrix standard scanning protocol	Patients with MDS, chronic myelomonocytic leukemia (CMMoL), and high risk AML were treated with sequential administration of methylation inhibitor drugs (5AC and entinostat).	Cel files were imported in GeneSpring GX and normalized by GC-RMA. Pairs of specimens passing quality control for hybridization and RNA integrity were analyzed by paired T test	GPL570	Weijia,,Zhang	weijia.zhang@mssm.edu	212-241-2883	Bioinformatics Lab	Department of Medicine	Mount Sinai School of Medicine	1425 Madison Avenue	New York	NY	10029	USA	ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM417nnn/GSM417419/GSM417419.CEL.gz	54675
GSM417420	Patient 05-D15	GSM417420	Public on Jun 20 2009	Jun 15 2009	Jun 19 2009	RNA	1	Day 15	Homo sapiens	diagnosis: MDS	cell type: CD34+	dose: 40 mg/m2/day 5-azacytidine	dose: 2 mg/m2/day entinostat	Enrolled patients were treated with sequential administration of 5AC and entinostat.  The study was approved by the Institutional Review Boards (IRB) for each institution, and all patients signed informed consent according to Health and Human Services guidelines.  Specific IRB approved informed consent was obtained for the laboratory research use of patient specimens.  5AC was administered subcutaneously for 10 consecutive days in doses of 30, 40, or 50 mg/m2/day.  Entinostat (2, 4, 6, or 8 mg/m2) was administered orally on days 3 and 10 of the 5AC treatment schedule in the course of a 28-29 day treatment cycle.	total RNA	RNA was isolated using Qiagen RNeasy Mini Kit with on-column DNAse treatment to remove genomic DNA	biotin	mRNA was subjected to two rounds of linear amplification and biotin labelling in second round was with the Ambion MessageAmp II kit with bio-C and bio-U as stated by manufacturer	9606	Hybridization cocktails containing 10 ug of fragmented cRNA was prepared using GeneChip Expression 3'-Amplification Reagents Hybridization Control Kit in a 200 ul final volume according to the manufacturers instructions	Affymetrix standard scanning protocol	Patients with MDS, chronic myelomonocytic leukemia (CMMoL), and high risk AML were treated with sequential administration of methylation inhibitor drugs (5AC and entinostat).	Cel files were imported in GeneSpring GX and normalized by GC-RMA. Pairs of specimens passing quality control for hybridization and RNA integrity were analyzed by paired T test	GPL570	Weijia,,Zhang	weijia.zhang@mssm.edu	212-241-2883	Bioinformatics Lab	Department of Medicine	Mount Sinai School of Medicine	1425 Madison Avenue	New York	NY	10029	USA	ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM417nnn/GSM417420/GSM417420.CEL.gz	54675
GSM417421	Patient 06-D0	GSM417421	Public on Jun 20 2009	Jun 15 2009	Jun 19 2009	RNA	1	Day 0	Homo sapiens	diagnosis: MDS	cell type: CD34+	dose: 40 mg/m2/day 5-azacytidine	dose: 2 mg/m2/day entinostat	Enrolled patients were treated with sequential administration of 5AC and entinostat.  The study was approved by the Institutional Review Boards (IRB) for each institution, and all patients signed informed consent according to Health and Human Services guidelines.  Specific IRB approved informed consent was obtained for the laboratory research use of patient specimens.  5AC was administered subcutaneously for 10 consecutive days in doses of 30, 40, or 50 mg/m2/day.  Entinostat (2, 4, 6, or 8 mg/m2) was administered orally on days 3 and 10 of the 5AC treatment schedule in the course of a 28-29 day treatment cycle.	total RNA	RNA was isolated using Qiagen RNeasy Mini Kit with on-column DNAse treatment to remove genomic DNA	biotin	mRNA was subjected to two rounds of linear amplification and biotin labelling in second round was with the Ambion MessageAmp II kit with bio-C and bio-U as stated by manufacturer	9606	Hybridization cocktails containing 10 ug of fragmented cRNA was prepared using GeneChip Expression 3'-Amplification Reagents Hybridization Control Kit in a 200 ul final volume according to the manufacturers instructions	Affymetrix standard scanning protocol	Patients with MDS, chronic myelomonocytic leukemia (CMMoL), and high risk AML were treated with sequential administration of methylation inhibitor drugs (5AC and entinostat).	Cel files were imported in GeneSpring GX and normalized by GC-RMA. Pairs of specimens passing quality control for hybridization and RNA integrity were analyzed by paired T test	GPL570	Weijia,,Zhang	weijia.zhang@mssm.edu	212-241-2883	Bioinformatics Lab	Department of Medicine	Mount Sinai School of Medicine	1425 Madison Avenue	New York	NY	10029	USA	ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM417nnn/GSM417421/GSM417421.CEL.gz	54675
GSM417422	Patient 06-D15	GSM417422	Public on Jun 20 2009	Jun 15 2009	Jun 19 2009	RNA	1	Day 15	Homo sapiens	diagnosis: MDS	cell type: CD34+	dose: 40 mg/m2/day 5-azacytidine	dose: 2 mg/m2/day entinostat	Enrolled patients were treated with sequential administration of 5AC and entinostat.  The study was approved by the Institutional Review Boards (IRB) for each institution, and all patients signed informed consent according to Health and Human Services guidelines.  Specific IRB approved informed consent was obtained for the laboratory research use of patient specimens.  5AC was administered subcutaneously for 10 consecutive days in doses of 30, 40, or 50 mg/m2/day.  Entinostat (2, 4, 6, or 8 mg/m2) was administered orally on days 3 and 10 of the 5AC treatment schedule in the course of a 28-29 day treatment cycle.	total RNA	RNA was isolated using Qiagen RNeasy Mini Kit with on-column DNAse treatment to remove genomic DNA	biotin	mRNA was subjected to two rounds of linear amplification and biotin labelling in second round was with the Ambion MessageAmp II kit with bio-C and bio-U as stated by manufacturer	9606	Hybridization cocktails containing 10 ug of fragmented cRNA was prepared using GeneChip Expression 3'-Amplification Reagents Hybridization Control Kit in a 200 ul final volume according to the manufacturers instructions	Affymetrix standard scanning protocol	Patients with MDS, chronic myelomonocytic leukemia (CMMoL), and high risk AML were treated with sequential administration of methylation inhibitor drugs (5AC and entinostat).	Cel files were imported in GeneSpring GX and normalized by GC-RMA. Pairs of specimens passing quality control for hybridization and RNA integrity were analyzed by paired T test	GPL570	Weijia,,Zhang	weijia.zhang@mssm.edu	212-241-2883	Bioinformatics Lab	Department of Medicine	Mount Sinai School of Medicine	1425 Madison Avenue	New York	NY	10029	USA	ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM417nnn/GSM417422/GSM417422.CEL.gz	54675
GSM417423	Patient 08-D0	GSM417423	Public on Jun 20 2009	Jun 15 2009	Jun 19 2009	RNA	1	Day 0	Homo sapiens	diagnosis: MDS	cell type: CD34+	dose: 50 mg/m2/day 5-azacytidine	dose: 4 mg/m2/day entinostat	Enrolled patients were treated with sequential administration of 5AC and entinostat.  The study was approved by the Institutional Review Boards (IRB) for each institution, and all patients signed informed consent according to Health and Human Services guidelines.  Specific IRB approved informed consent was obtained for the laboratory research use of patient specimens.  5AC was administered subcutaneously for 10 consecutive days in doses of 30, 40, or 50 mg/m2/day.  Entinostat (2, 4, 6, or 8 mg/m2) was administered orally on days 3 and 10 of the 5AC treatment schedule in the course of a 28-29 day treatment cycle.	total RNA	RNA was isolated using Qiagen RNeasy Mini Kit with on-column DNAse treatment to remove genomic DNA	biotin	mRNA was subjected to two rounds of linear amplification and biotin labelling in second round was with the Ambion MessageAmp II kit with bio-C and bio-U as stated by manufacturer	9606	Hybridization cocktails containing 10 ug of fragmented cRNA was prepared using GeneChip Expression 3'-Amplification Reagents Hybridization Control Kit in a 200 ul final volume according to the manufacturers instructions	Affymetrix standard scanning protocol	Patients with MDS, chronic myelomonocytic leukemia (CMMoL), and high risk AML were treated with sequential administration of methylation inhibitor drugs (5AC and entinostat).	Cel files were imported in GeneSpring GX and normalized by GC-RMA. Pairs of specimens passing quality control for hybridization and RNA integrity were analyzed by paired T test	GPL570	Weijia,,Zhang	weijia.zhang@mssm.edu	212-241-2883	Bioinformatics Lab	Department of Medicine	Mount Sinai School of Medicine	1425 Madison Avenue	New York	NY	10029	USA	ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM417nnn/GSM417423/GSM417423.CEL.gz	54675
GSM417424	Patient 08-D15	GSM417424	Public on Jun 20 2009	Jun 15 2009	Jun 19 2009	RNA	1	Day 15	Homo sapiens	diagnosis: MDS	cell type: CD34+	dose: 50 mg/m2/day 5-azacytidine	dose: 4 mg/m2/day entinostat	Enrolled patients were treated with sequential administration of 5AC and entinostat.  The study was approved by the Institutional Review Boards (IRB) for each institution, and all patients signed informed consent according to Health and Human Services guidelines.  Specific IRB approved informed consent was obtained for the laboratory research use of patient specimens.  5AC was administered subcutaneously for 10 consecutive days in doses of 30, 40, or 50 mg/m2/day.  Entinostat (2, 4, 6, or 8 mg/m2) was administered orally on days 3 and 10 of the 5AC treatment schedule in the course of a 28-29 day treatment cycle.	total RNA	RNA was isolated using Qiagen RNeasy Mini Kit with on-column DNAse treatment to remove genomic DNA	biotin	mRNA was subjected to two rounds of linear amplification and biotin labelling in second round was with the Ambion MessageAmp II kit with bio-C and bio-U as stated by manufacturer	9606	Hybridization cocktails containing 10 ug of fragmented cRNA was prepared using GeneChip Expression 3'-Amplification Reagents Hybridization Control Kit in a 200 ul final volume according to the manufacturers instructions	Affymetrix standard scanning protocol	Patients with MDS, chronic myelomonocytic leukemia (CMMoL), and high risk AML were treated with sequential administration of methylation inhibitor drugs (5AC and entinostat).	Cel files were imported in GeneSpring GX and normalized by GC-RMA. Pairs of specimens passing quality control for hybridization and RNA integrity were analyzed by paired T test	GPL570	Weijia,,Zhang	weijia.zhang@mssm.edu	212-241-2883	Bioinformatics Lab	Department of Medicine	Mount Sinai School of Medicine	1425 Madison Avenue	New York	NY	10029	USA	ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM417nnn/GSM417424/GSM417424.CEL.gz	54675
GSM417425	Patient 09-D0	GSM417425	Public on Jun 20 2009	Jun 15 2009	Jun 19 2009	RNA	1	Day 0	Homo sapiens	diagnosis: AML-TLD	cell type: CD34+	dose: 40 mg/m2/day 5-azacytidine	dose: 4 mg/m2/day entinostat	Enrolled patients were treated with sequential administration of 5AC and entinostat.  The study was approved by the Institutional Review Boards (IRB) for each institution, and all patients signed informed consent according to Health and Human Services guidelines.  Specific IRB approved informed consent was obtained for the laboratory research use of patient specimens.  5AC was administered subcutaneously for 10 consecutive days in doses of 30, 40, or 50 mg/m2/day.  Entinostat (2, 4, 6, or 8 mg/m2) was administered orally on days 3 and 10 of the 5AC treatment schedule in the course of a 28-29 day treatment cycle.	total RNA	RNA was isolated using Qiagen RNeasy Mini Kit with on-column DNAse treatment to remove genomic DNA	biotin	mRNA was subjected to two rounds of linear amplification and biotin labelling in second round was with the Ambion MessageAmp II kit with bio-C and bio-U as stated by manufacturer	9606	Hybridization cocktails containing 10 ug of fragmented cRNA was prepared using GeneChip Expression 3'-Amplification Reagents Hybridization Control Kit in a 200 ul final volume according to the manufacturers instructions	Affymetrix standard scanning protocol	Patients with MDS, chronic myelomonocytic leukemia (CMMoL), and high risk AML were treated with sequential administration of methylation inhibitor drugs (5AC and entinostat).	Cel files were imported in GeneSpring GX and normalized by GC-RMA. Pairs of specimens passing quality control for hybridization and RNA integrity were analyzed by paired T test	GPL570	Weijia,,Zhang	weijia.zhang@mssm.edu	212-241-2883	Bioinformatics Lab	Department of Medicine	Mount Sinai School of Medicine	1425 Madison Avenue	New York	NY	10029	USA	ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM417nnn/GSM417425/GSM417425.CEL.gz	54675
GSM417426	Patient 09-D15	GSM417426	Public on Jun 20 2009	Jun 15 2009	Jun 19 2009	RNA	1	Day 15	Homo sapiens	diagnosis: AML-TLD	cell type: CD34+	dose: 40 mg/m2/day 5-azacytidine	dose: 4 mg/m2/day entinostat	Enrolled patients were treated with sequential administration of 5AC and entinostat.  The study was approved by the Institutional Review Boards (IRB) for each institution, and all patients signed informed consent according to Health and Human Services guidelines.  Specific IRB approved informed consent was obtained for the laboratory research use of patient specimens.  5AC was administered subcutaneously for 10 consecutive days in doses of 30, 40, or 50 mg/m2/day.  Entinostat (2, 4, 6, or 8 mg/m2) was administered orally on days 3 and 10 of the 5AC treatment schedule in the course of a 28-29 day treatment cycle.	total RNA	RNA was isolated using Qiagen RNeasy Mini Kit with on-column DNAse treatment to remove genomic DNA	biotin	mRNA was subjected to two rounds of linear amplification and biotin labelling in second round was with the Ambion MessageAmp II kit with bio-C and bio-U as stated by manufacturer	9606	Hybridization cocktails containing 10 ug of fragmented cRNA was prepared using GeneChip Expression 3'-Amplification Reagents Hybridization Control Kit in a 200 ul final volume according to the manufacturers instructions	Affymetrix standard scanning protocol	Patients with MDS, chronic myelomonocytic leukemia (CMMoL), and high risk AML were treated with sequential administration of methylation inhibitor drugs (5AC and entinostat).	Cel files were imported in GeneSpring GX and normalized by GC-RMA. Pairs of specimens passing quality control for hybridization and RNA integrity were analyzed by paired T test	GPL570	Weijia,,Zhang	weijia.zhang@mssm.edu	212-241-2883	Bioinformatics Lab	Department of Medicine	Mount Sinai School of Medicine	1425 Madison Avenue	New York	NY	10029	USA	ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM417nnn/GSM417426/GSM417426.CEL.gz	54675
GSM417427	Patient 12-D0	GSM417427	Public on Jun 20 2009	Jun 15 2009	Jun 19 2009	RNA	1	Day 0	Homo sapiens	diagnosis: MDS	cell type: CD34+	dose: 50 mg/m2/day 5-azacytidine	dose: 6 mg/m2/day entinostat	Enrolled patients were treated with sequential administration of 5AC and entinostat.  The study was approved by the Institutional Review Boards (IRB) for each institution, and all patients signed informed consent according to Health and Human Services guidelines.  Specific IRB approved informed consent was obtained for the laboratory research use of patient specimens.  5AC was administered subcutaneously for 10 consecutive days in doses of 30, 40, or 50 mg/m2/day.  Entinostat (2, 4, 6, or 8 mg/m2) was administered orally on days 3 and 10 of the 5AC treatment schedule in the course of a 28-29 day treatment cycle.	total RNA	RNA was isolated using Qiagen RNeasy Mini Kit with on-column DNAse treatment to remove genomic DNA	biotin	mRNA was subjected to two rounds of linear amplification and biotin labelling in second round was with the Ambion MessageAmp II kit with bio-C and bio-U as stated by manufacturer	9606	Hybridization cocktails containing 10 ug of fragmented cRNA was prepared using GeneChip Expression 3'-Amplification Reagents Hybridization Control Kit in a 200 ul final volume according to the manufacturers instructions	Affymetrix standard scanning protocol	Patients with MDS, chronic myelomonocytic leukemia (CMMoL), and high risk AML were treated with sequential administration of methylation inhibitor drugs (5AC and entinostat).	Cel files were imported in GeneSpring GX and normalized by GC-RMA. Pairs of specimens passing quality control for hybridization and RNA integrity were analyzed by paired T test	GPL570	Weijia,,Zhang	weijia.zhang@mssm.edu	212-241-2883	Bioinformatics Lab	Department of Medicine	Mount Sinai School of Medicine	1425 Madison Avenue	New York	NY	10029	USA	ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM417nnn/GSM417427/GSM417427.CEL.gz	54675
GSM417428	Patient 12-D15	GSM417428	Public on Jun 20 2009	Jun 15 2009	Jun 19 2009	RNA	1	Day 15	Homo sapiens	diagnosis: MDS	cell type: CD34+	dose: 50 mg/m2/day 5-azacytidine	dose: 6 mg/m2/day entinostat	Enrolled patients were treated with sequential administration of 5AC and entinostat.  The study was approved by the Institutional Review Boards (IRB) for each institution, and all patients signed informed consent according to Health and Human Services guidelines.  Specific IRB approved informed consent was obtained for the laboratory research use of patient specimens.  5AC was administered subcutaneously for 10 consecutive days in doses of 30, 40, or 50 mg/m2/day.  Entinostat (2, 4, 6, or 8 mg/m2) was administered orally on days 3 and 10 of the 5AC treatment schedule in the course of a 28-29 day treatment cycle.	total RNA	RNA was isolated using Qiagen RNeasy Mini Kit with on-column DNAse treatment to remove genomic DNA	biotin	mRNA was subjected to two rounds of linear amplification and biotin labelling in second round was with the Ambion MessageAmp II kit with bio-C and bio-U as stated by manufacturer	9606	Hybridization cocktails containing 10 ug of fragmented cRNA was prepared using GeneChip Expression 3'-Amplification Reagents Hybridization Control Kit in a 200 ul final volume according to the manufacturers instructions	Affymetrix standard scanning protocol	Patients with MDS, chronic myelomonocytic leukemia (CMMoL), and high risk AML were treated with sequential administration of methylation inhibitor drugs (5AC and entinostat).	Cel files were imported in GeneSpring GX and normalized by GC-RMA. Pairs of specimens passing quality control for hybridization and RNA integrity were analyzed by paired T test	GPL570	Weijia,,Zhang	weijia.zhang@mssm.edu	212-241-2883	Bioinformatics Lab	Department of Medicine	Mount Sinai School of Medicine	1425 Madison Avenue	New York	NY	10029	USA	ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM417nnn/GSM417428/GSM417428.CEL.gz	54675
GSM417429	Patient 13-D0	GSM417429	Public on Jun 20 2009	Jun 15 2009	Jun 19 2009	RNA	1	Day 0	Homo sapiens	diagnosis: MDS	cell type: CD34+	dose: 50 mg/m2/day 5-azacytidine	dose: 6 mg/m2/day entinostat	Enrolled patients were treated with sequential administration of 5AC and entinostat.  The study was approved by the Institutional Review Boards (IRB) for each institution, and all patients signed informed consent according to Health and Human Services guidelines.  Specific IRB approved informed consent was obtained for the laboratory research use of patient specimens.  5AC was administered subcutaneously for 10 consecutive days in doses of 30, 40, or 50 mg/m2/day.  Entinostat (2, 4, 6, or 8 mg/m2) was administered orally on days 3 and 10 of the 5AC treatment schedule in the course of a 28-29 day treatment cycle.	total RNA	RNA was isolated using Qiagen RNeasy Mini Kit with on-column DNAse treatment to remove genomic DNA	biotin	mRNA was subjected to two rounds of linear amplification and biotin labelling in second round was with the Ambion MessageAmp II kit with bio-C and bio-U as stated by manufacturer	9606	Hybridization cocktails containing 10 ug of fragmented cRNA was prepared using GeneChip Expression 3'-Amplification Reagents Hybridization Control Kit in a 200 ul final volume according to the manufacturers instructions	Affymetrix standard scanning protocol	Patients with MDS, chronic myelomonocytic leukemia (CMMoL), and high risk AML were treated with sequential administration of methylation inhibitor drugs (5AC and entinostat).	Cel files were imported in GeneSpring GX and normalized by GC-RMA. Pairs of specimens passing quality control for hybridization and RNA integrity were analyzed by paired T test	GPL570	Weijia,,Zhang	weijia.zhang@mssm.edu	212-241-2883	Bioinformatics Lab	Department of Medicine	Mount Sinai School of Medicine	1425 Madison Avenue	New York	NY	10029	USA	ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM417nnn/GSM417429/GSM417429.CEL.gz	54675
GSM417430	Patient 13-D15	GSM417430	Public on Jun 20 2009	Jun 15 2009	Jun 19 2009	RNA	1	Day 15	Homo sapiens	diagnosis: MDS	cell type: CD34+	dose: 50 mg/m2/day 5-azacytidine	dose: 6 mg/m2/day entinostat	Enrolled patients were treated with sequential administration of 5AC and entinostat.  The study was approved by the Institutional Review Boards (IRB) for each institution, and all patients signed informed consent according to Health and Human Services guidelines.  Specific IRB approved informed consent was obtained for the laboratory research use of patient specimens.  5AC was administered subcutaneously for 10 consecutive days in doses of 30, 40, or 50 mg/m2/day.  Entinostat (2, 4, 6, or 8 mg/m2) was administered orally on days 3 and 10 of the 5AC treatment schedule in the course of a 28-29 day treatment cycle.	total RNA	RNA was isolated using Qiagen RNeasy Mini Kit with on-column DNAse treatment to remove genomic DNA	biotin	mRNA was subjected to two rounds of linear amplification and biotin labelling in second round was with the Ambion MessageAmp II kit with bio-C and bio-U as stated by manufacturer	9606	Hybridization cocktails containing 10 ug of fragmented cRNA was prepared using GeneChip Expression 3'-Amplification Reagents Hybridization Control Kit in a 200 ul final volume according to the manufacturers instructions	Affymetrix standard scanning protocol	Patients with MDS, chronic myelomonocytic leukemia (CMMoL), and high risk AML were treated with sequential administration of methylation inhibitor drugs (5AC and entinostat).	Cel files were imported in GeneSpring GX and normalized by GC-RMA. Pairs of specimens passing quality control for hybridization and RNA integrity were analyzed by paired T test	GPL570	Weijia,,Zhang	weijia.zhang@mssm.edu	212-241-2883	Bioinformatics Lab	Department of Medicine	Mount Sinai School of Medicine	1425 Madison Avenue	New York	NY	10029	USA	ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM417nnn/GSM417430/GSM417430.CEL.gz	54675
GSM417431	Patient 17-D0	GSM417431	Public on Jun 20 2009	Jun 15 2009	Jun 19 2009	RNA	1	Day 0	Homo sapiens	diagnosis: MDS	cell type: CD34+	dose: 50 mg/m2/day 5-azacytidine	dose: 8 mg/m2/day entinostat	Enrolled patients were treated with sequential administration of 5AC and entinostat.  The study was approved by the Institutional Review Boards (IRB) for each institution, and all patients signed informed consent according to Health and Human Services guidelines.  Specific IRB approved informed consent was obtained for the laboratory research use of patient specimens.  5AC was administered subcutaneously for 10 consecutive days in doses of 30, 40, or 50 mg/m2/day.  Entinostat (2, 4, 6, or 8 mg/m2) was administered orally on days 3 and 10 of the 5AC treatment schedule in the course of a 28-29 day treatment cycle.	total RNA	RNA was isolated using Qiagen RNeasy Mini Kit with on-column DNAse treatment to remove genomic DNA	biotin	mRNA was subjected to two rounds of linear amplification and biotin labelling in second round was with the Ambion MessageAmp II kit with bio-C and bio-U as stated by manufacturer	9606	Hybridization cocktails containing 10 ug of fragmented cRNA was prepared using GeneChip Expression 3'-Amplification Reagents Hybridization Control Kit in a 200 ul final volume according to the manufacturers instructions	Affymetrix standard scanning protocol	Patients with MDS, chronic myelomonocytic leukemia (CMMoL), and high risk AML were treated with sequential administration of methylation inhibitor drugs (5AC and entinostat).	Cel files were imported in GeneSpring GX and normalized by GC-RMA. Pairs of specimens passing quality control for hybridization and RNA integrity were analyzed by paired T test	GPL570	Weijia,,Zhang	weijia.zhang@mssm.edu	212-241-2883	Bioinformatics Lab	Department of Medicine	Mount Sinai School of Medicine	1425 Madison Avenue	New York	NY	10029	USA	ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM417nnn/GSM417431/GSM417431.CEL.gz	54675
GSM417432	Patient 17-D15	GSM417432	Public on Jun 20 2009	Jun 15 2009	Jun 19 2009	RNA	1	Day 15	Homo sapiens	diagnosis: MDS	cell type: CD34+	dose: 50 mg/m2/day 5-azacytidine	dose: 8 mg/m2/day entinostat	Enrolled patients were treated with sequential administration of 5AC and entinostat.  The study was approved by the Institutional Review Boards (IRB) for each institution, and all patients signed informed consent according to Health and Human Services guidelines.  Specific IRB approved informed consent was obtained for the laboratory research use of patient specimens.  5AC was administered subcutaneously for 10 consecutive days in doses of 30, 40, or 50 mg/m2/day.  Entinostat (2, 4, 6, or 8 mg/m2) was administered orally on days 3 and 10 of the 5AC treatment schedule in the course of a 28-29 day treatment cycle.	total RNA	RNA was isolated using Qiagen RNeasy Mini Kit with on-column DNAse treatment to remove genomic DNA	biotin	mRNA was subjected to two rounds of linear amplification and biotin labelling in second round was with the Ambion MessageAmp II kit with bio-C and bio-U as stated by manufacturer	9606	Hybridization cocktails containing 10 ug of fragmented cRNA was prepared using GeneChip Expression 3'-Amplification Reagents Hybridization Control Kit in a 200 ul final volume according to the manufacturers instructions	Affymetrix standard scanning protocol	Patients with MDS, chronic myelomonocytic leukemia (CMMoL), and high risk AML were treated with sequential administration of methylation inhibitor drugs (5AC and entinostat).	Cel files were imported in GeneSpring GX and normalized by GC-RMA. Pairs of specimens passing quality control for hybridization and RNA integrity were analyzed by paired T test	GPL570	Weijia,,Zhang	weijia.zhang@mssm.edu	212-241-2883	Bioinformatics Lab	Department of Medicine	Mount Sinai School of Medicine	1425 Madison Avenue	New York	NY	10029	USA	ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM417nnn/GSM417432/GSM417432.CEL.gz	54675
GSM417433	Patient 24-D0	GSM417433	Public on Jun 20 2009	Jun 15 2009	Jun 19 2009	RNA	1	Day 0	Homo sapiens	diagnosis: CMMoL	cell type: CD34+	dose: 30 mg/m2/day 5-azacytidine	dose: 2 mg/m2/day entinostat	Enrolled patients were treated with sequential administration of 5AC and entinostat.  The study was approved by the Institutional Review Boards (IRB) for each institution, and all patients signed informed consent according to Health and Human Services guidelines.  Specific IRB approved informed consent was obtained for the laboratory research use of patient specimens.  5AC was administered subcutaneously for 10 consecutive days in doses of 30, 40, or 50 mg/m2/day.  Entinostat (2, 4, 6, or 8 mg/m2) was administered orally on days 3 and 10 of the 5AC treatment schedule in the course of a 28-29 day treatment cycle.	total RNA	RNA was isolated using Qiagen RNeasy Mini Kit with on-column DNAse treatment to remove genomic DNA	biotin	mRNA was subjected to two rounds of linear amplification and biotin labelling in second round was with the Ambion MessageAmp II kit with bio-C and bio-U as stated by manufacturer	9606	Hybridization cocktails containing 10 ug of fragmented cRNA was prepared using GeneChip Expression 3'-Amplification Reagents Hybridization Control Kit in a 200 ul final volume according to the manufacturers instructions	Affymetrix standard scanning protocol	Patients with MDS, chronic myelomonocytic leukemia (CMMoL), and high risk AML were treated with sequential administration of methylation inhibitor drugs (5AC and entinostat).	Cel files were imported in GeneSpring GX and normalized by GC-RMA. Pairs of specimens passing quality control for hybridization and RNA integrity were analyzed by paired T test	GPL570	Weijia,,Zhang	weijia.zhang@mssm.edu	212-241-2883	Bioinformatics Lab	Department of Medicine	Mount Sinai School of Medicine	1425 Madison Avenue	New York	NY	10029	USA	ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM417nnn/GSM417433/GSM417433.CEL.gz	54675
GSM417434	Patient 24-D15	GSM417434	Public on Jun 20 2009	Jun 15 2009	Jun 19 2009	RNA	1	Day 15	Homo sapiens	diagnosis: CMMoL	cell type: CD34+	dose: 30 mg/m2/day 5-azacytidine	dose: 2 mg/m2/day entinostat	Enrolled patients were treated with sequential administration of 5AC and entinostat.  The study was approved by the Institutional Review Boards (IRB) for each institution, and all patients signed informed consent according to Health and Human Services guidelines.  Specific IRB approved informed consent was obtained for the laboratory research use of patient specimens.  5AC was administered subcutaneously for 10 consecutive days in doses of 30, 40, or 50 mg/m2/day.  Entinostat (2, 4, 6, or 8 mg/m2) was administered orally on days 3 and 10 of the 5AC treatment schedule in the course of a 28-29 day treatment cycle.	total RNA	RNA was isolated using Qiagen RNeasy Mini Kit with on-column DNAse treatment to remove genomic DNA	biotin	mRNA was subjected to two rounds of linear amplification and biotin labelling in second round was with the Ambion MessageAmp II kit with bio-C and bio-U as stated by manufacturer	9606	Hybridization cocktails containing 10 ug of fragmented cRNA was prepared using GeneChip Expression 3'-Amplification Reagents Hybridization Control Kit in a 200 ul final volume according to the manufacturers instructions	Affymetrix standard scanning protocol	Patients with MDS, chronic myelomonocytic leukemia (CMMoL), and high risk AML were treated with sequential administration of methylation inhibitor drugs (5AC and entinostat).	Cel files were imported in GeneSpring GX and normalized by GC-RMA. Pairs of specimens passing quality control for hybridization and RNA integrity were analyzed by paired T test	GPL570	Weijia,,Zhang	weijia.zhang@mssm.edu	212-241-2883	Bioinformatics Lab	Department of Medicine	Mount Sinai School of Medicine	1425 Madison Avenue	New York	NY	10029	USA	ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM417nnn/GSM417434/GSM417434.CEL.gz	54675
